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Objective: It has been demonstrated that signals from the inhibitory receptor B and T lymphocyte attenuator
(BTLA) are involved in regulating the pathogenesis of infectious diseases. However, the expression and anatomical
distribution of BTLA and its ligand, the herpes virus entry mediator (HVEM), have not yet been determined in cases
of HBV-related acute-on-chronic liver failure (HBV-ACLF) patients.
Methods: In this study, the expression of BTLA and HVEM in liver tissues from HBV-ACLF, chronic hepatitis B (CHB)
patients and healthy individuals was analyzed by immunohistochemistry.
Results: The results of this analysis demonstrated that both molecules were observed in the HBV-ACLF samples
and that their expression was chiefly in the infiltrating inflammatory cells and the damaged bile ducts. However,
they were absent in liver sections from CHB patients and healthy controls. Immunofluorescence double-staining
indicated that BTLA was found on CK-18+ epithelial cells, CD31+ endothelial cells, CD68+ macrophages, CD56+ NK
cells, CD16+ monocytes, CD3+ , CD8+ T cells, and Foxp3+ regulatory T cells (Treg). By contrast, HVEM expression was
restricted to CK18+ epithelial cells and CD68+ macrophages. Moreover, the expression of several members of the B7
superfamily, including PD-L1, PD-L2, B7-H3 and B7-H4, was also detected in these liver tissues, and these proteins
were co-expressed with HVEM. Interestingly, the expression of fibrinogen-like protein 2 (FGL2), a virus-induced
procoagulant molecule, was also found in liver sections from HBV-ACLF, this molecule also co-expresses with BTLA
and HVEM.
Conclusions: These results suggest that BTLA-HVEM signaling is likely to affect the pathogenesis of HBV-ACLF, a
clear understanding of the functional roles of these proteins should further elucidate the disease process.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/8080806838149123
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Hepatitis B virus (HBV) infection causes a spectrum of
diseases, such as chronic hepatitis B (CHB), liver cirrhosis,
primary hepatocellular carcinoma, and acute-on-chronic
liver failure (ACLF) [1]. HBV-ACLF is a clinical syndrome
that is defined as acute hepatic insult with either diagnosed* Correspondence: yongwench@163.com
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reproduction in any medium, provided the oror undiagnosed chronic liver disease [2,3]. The hallmark of
HBV-ACLF is the extreme rapidity of the necromicroin-
flammatory process, which results in hepatocellular necro-
sis within several weeks [4]. Currently, liver transplantation
is the best method for clinical treatment of this disease.
However, the mortality of HBV-ACLF remains very high. It
is essential to identify more specific markers for the diag-
nosis of this disease.
B and T lymphocyte attenuator (BTLA) is a member of
the CD28 superfamily [5]. BTLA-deficient (BTLA−/−)
mice are more sensitive to experimental autoimmune en-
cephalomyelitis (EAE) [5], allergic airway inflammationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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graft rejection [8] than normal individuals, indicating that
this receptor plays an essential role in maintaining periph-
eral tolerance. In infectious disease models, for instance, it
has been found that an interruption of BTLA signaling
causes the augmentation of the virus-specific cytotoxic
lymphocyte (CTL) response, promoting the early clear-
ance of both Listeria bacteria and CMV infection [9,10].
These studies generally indicate that BTLA appears to be
a negative regulator. Herpes virus entry mediator
(HVEM), an immunoregulatory molecule that belongs
to the tumor necrosis factor (TNF) receptor super-
family, has been identified as the potential ‘ligand’ for
BTLA [11]. The cross-linking of BTLA with HVEM
results in the phosphorylation of the tyrosines on
BTLA and the recruitment of phosphatases, including
SHP-1 and SHP-2, to the ITIM motif in the cytoplas-
mic region of BTLA, this response reduces TCR sig-
naling and eventually diminishes T cell activation
[12].
Our previous work has demonstrated that BTLA ac-
tively participates in the pathogenesis of fulminant hepa-
titis that is caused by infection with murine hepatitis
virus strain 3 (MHV-3) [13]. However, uncertainty
remains regarding the expression and anatomical distri-
bution of BTLA and HVEM in livers from HBV-ACLF
patients. In this study, we used immunohistochemistry
to analyze the expression of both proteins in liver
biopsies from HBV-ACLF patients and further
assessed the phenotypes via immunofluorescence
double staining.Materials and methods
Patients
Four samples from autopsies of HBV-ACLF patients, 16
samples from liver biopsies of CHB patients, and 5 sam-
ples of liver tissue from normal individuals were used in
this study. All of the CHB patients were seropositive for
hepatitis B surface Ag (HBs) and hepatitis B e Ag (HBe)
for at least 12 months and were negative for antibodies
against the human immunodeficiency virus, hepatitis C
virus, and hepatitis D virus, additional parameters for
these CHB patients have been reported in our previous
work [14,15]. All of the patients were admitted to the
Center of Infectious Disease, Southwest Hospital
(Chongqing 400038, People’s Republic of China) from
June 2006 to January 2009. None of the CHB patients
were treated for chronic HBV infection for 6 months
prior to the liver sampling process. Sections of liver
tissue were scored in a blinded fashion to measure
their histological diagnoses. The study protocol was
approved by the Ethics Committee of the Third Military
Medical University review board.Immunohistochemistry
The protocol that was used for immunohistochemistry
was in accordance with previously published procedures,
with slight modifications [14]. Briefly, paraffin-embedded
tissue blocks were cut into 2~3 μm sections and
mounted on poly-L-lysine-charged glass slides. After the
sections were dewaxed and rehydrated, antigen retrieval
was performed by microwaving these sections in 10 mM
citrate buffer (pH 6.0). The sections were cooled to
room temperature (RT), and the endogenous peroxidase
was blocked by incubation with a solution of 0.5%
hydrogen peroxide (H2O2) in 50% methanol for 1 h. The
sections were then incubated in 3% BSA plus 0.1% Noni-
det P-40 in PBS for 1 h at RT to block nonspecific bind-
ing. The sections were then incubated overnight at 4°C
with primary anti-BTLA (1:100, rabbit IgG; Santa Cruz,
San Diego, CA, USA), anti-HBs (1:100, rabbit IgG;
Abcam, Cambridge, MA, USA), anti-CD68 (1:100, clone:
3F103; Santa Cruz), anti-CD16 (1:100, clone: 2Q1240;
Santa Cruz), anti-CD3 (1:50, clone: F7.2.38; Dako,
Copenhagen, Denmark) or anti-fibrinogen (1:100; Dako)
antibodies that had been diluted in 1% BSA. After the
sections were washed, they were incubated with the cor-
responding secondary antibodies for 1 h at RT. The Vec-
tastain ABC kit (Vector Laboratories, Burlingame, CA,
USA) was used to implement the avidin–biotin complex
approach in accordance with the manufacturer’s ins-
tructions. Sections that were incubated with isotype-
matched, concentration-matched immunoglobulin with-
out primary antibodies were used as isotype controls.
Peroxidase activity was visualized with the DAB Elite kit
(K3465, Dako), and the brown coloration of tissues
represented positive staining. The sections were lightly
counterstained with hematoxylin, dehydrated through
an ethanol series to xylene, and mounted. Finally, the
sample sections were viewed using a light microscope
(Zeiss Axioplan 2, Berlin, Germany).
Immunofluorescence double staining
For immunofluorescence double staining, sections were
incubated with primary anti-BTLA and anti-HVEM anti-
bodies at 4°C overnight. After the sections were washed with
PBS (5 min/wash × 3 washes), they were incubated with
Alexa FluorW 555-conjugated goat anti-mouse/rabbit IgG
antibodies (Invitrogen, San Diego, CA, USA) for 1 h. Subse-
quently, the sections were further incubated with anti-CD3,
anti-CD8 (1:50, clone: C8/144B; Dako, Denmark), anti-CD56
(1:50; Santa Cruz), anti-B7-H1, (1:100, clone: 29E.2A3; kindly
provided by Dr. Gordon J. Freeman (Department of Medical
Oncology, Dana-Farber Cancer Institute, Harvard Medical
School, USA)), anti-B7-DC (either 1:50, polyclonal goat IgG;
R&D Systems or 1:100, clone: 24F.7G12; kindly provided by
Dr. Gordon J Freeman), anti-PD-1 (2 μg/ml, AF1086; R&D
Systems), anti-CD68, anti-FGL2 (1:100, clone: 4H5; Santa
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Santa Cruz), or anti-FGL2 (1:100; Santa Cruz) antibodies
at 4°C overnight and incubated with Alexa FluorW 488-
conjugated goat anti-mouse/rabbit IgG1 antibodies (Invitro-
gen) for an additional 1 h. Finally, the sections were incu-
bated with 1 μg/ml DAPI (Sigma, St. Louis, MO, USA) for
10 min to stain the nuclei. Sections incubated with the ap-
propriate isotype control primary antibodies and fluores-
cently labeled secondary antibodies were used as negative
controls. The results were analyzed using fluorescence mi-
croscopy (Zeiss Axioplan 2).Results
The pathologic characteristics of liver tissue from
HBV-ACLF
To address the relevance of BTLA and HVEM expres-
sion in human viral hepatitis, four liver biopsies from
patients with biochemical, histological, and clinical evi-
dence of HBV-ACLF, sixteen cases of CHB patients and
five cases of healthy individuals were collected in this
study. Severe hepatocyte necrosis, ballooning degener-
ation, and collapse of the parenchyma were found in the
liver tissue from HBV-ACLF patients, as demonstrated
by H&E staining (Figure 1A). In parallel, a cohort of
HBs+ hepatocytes (Figure 1B), infiltrating CD68+ macro-
phages (Figure 1C), CD3+ T cells (Figure 1D), CD16+
monocytes (Figure 1E) and a high level of fibrinogen
deposited in the damaged hepatocytes (Figure 1F) were
also detected in these samples. Based on the histological
and immunophenotypic findings from the examined
samples, we concluded that these four cases were accur-
ately diagnosed as typical instances of ACLF.Figure 1 The morphology of liver tissue from patients with HBV-relat
demonstrated that liver tissue sections from HBV-ACLF patients have sever
the parenchyma; immunohistochemistry showed that (B) the expression of
cohort of (C) CD68+ macrophages, (D) CD3+ T cells, and (E) CD16+ monoc
throughout the livers of HBV-ACLF patients. The arrows indicate positive ceThe expression and anatomical distribution of BTLA in
sections from HBV-ACLF
The expression of BTLA in liver samples from HBV-
ACLF patients, CHB patients and healthy individuals
was detected by immunohistochemistry. The results
showed that BTLA was absent in normal liver tissues
(Figure 2A) and in the 16 samples from CHB patients
(Figure 2B). In addition, no positive staining was
observed in the sections incubated with rabbit IgG1 iso-
type antibodies (data not shown). Nevertheless, strongly
BTLA+ cells were observed in the benign bile ducts
(Figure 2C) and in the infiltrating inflammatory cells
(Figure 2D) of these four cases of HBV-ACLF.
The phenotypes of BTLA+ cells in liver tissues from
HBV-ACLF patients were further examined by immuno-
fluorescence double staining. From these analyses, the
expression of BTLA was observed on CK-18+ epithelial
cells, CD31+ endothelial cells, CD68+ macrophages,
CD56+ NK cells, CD16+ monocytes, CD3+ CD8+ T cells,
and Foxp3+ regulatory T cells (Treg), but this expression
was completely absent on PD-1+ cells (Figure 3).The expression and distribution of HVEM in sections from
HBV-ACLF
The expression of HVEM in these collected liver sam-
ples was detected by immunofluorescence staining,
which indicated that HVEM-positive cells were observed
in all of the liver samples from HBV-ACLF patients. This
protein was found on cell membranes and in the cyto-
plasm, and its expression was chiefly found in damaged
bile ducts (Figure 4B) as well as in certain infiltrating in-
flammatory cells (Figure 4C), which were distributeded acute-on-chronic liver failure (HBV-ACLF). (A) HE staining
e necrosis, hepatocytes with ballooning degeneration and collapse of
HBsAg was found in hepatocytes of HBV-ACLF patients and that a
ytes and (F) fibrinogen+ cells were infiltrated and distributed
lls, and the scale bar indicates 20 μm.
Figure 2 The expression of BTLA in liver tissues from HBV-related acute-on-chronic liver failure (HBV-ACLF) patients, as detected by
immunohistochemistry. (A) BTLA expression was absent in normal liver sections; (B) BTLA expression was absent in liver sections from CHB; (C)
strong BTLA staining was observed in benign bile ducts sections from HBV-ACLF patients; (D) strong BTLA staining was observed on infiltrating
lymphocytes of sections from HBV-ACLF patients. The arrows indicate infiltrating positive cells, arrowhead indicated the capillaries. The scale bar
indicates 20 μm.
Figure 3 The morphology of BTLA+ cells in liver tissues from patients with HBV-related acute-on-chronic liver failure (HBV-ACLF) was
detected by immunofluorescence double staining. Immunofluorescence double staining revealed that BTLA was expressed on CK-18+ epithelial
cells, CD31+ endothelial cells, CD68+ macrophages, CD56+ NK cells, CD16+ monocytes, CD3+ CD8+ T cells, and Foxp3+ regulatory T cells (Treg),
whereas BLTA was absent on PD-1+ cells. The arrow indicates positive cells. The nuclei were stained with DAPI, and the scale bar indicates 20 μm.
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Figure 4 The expression of HVEM in liver tissues from patients with HBV-related acute-on-chronic liver failure (HBV-ACLF), as detected
by immunofluorescence staining. (A) HVEM was absence on sections from normal individuals. The bile ducts (B) and infiltrating lymphocytes
(C) (indicated by arrowhead) of liver sections from HBV-ACLF patients are positive for HVEM. (D) The expression of HVEM in bile ducts was also
found in two cases of CHB. (E) Immunofluorescence double staining demonstrated that HVEM was expressed on CK-18+ epithelial cells and CD68
+macrophages, whereas it was absent on CD3+ T cells, CD8+ T cells, CD16+ monocytes, and CD31+ endothelial cells. The arrows indicate positive
cells. The nuclei were stained with DAPI, and the scale bar indicates 20 μm.
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cases (2/16) of CHB were positive for HVEM, and the
expression of HVEM in these instances was restricted to
the damaged bile ducts (Figure 4D). However, normal
liver tissues were negative for HVEM (Figure 4A). These
results indicate that the expression of HVEM was
induced in liver samples from HBV-ACLF patients.
The phenotypes of HVEM+-cells within HBV-ACLF
liver sections were further examined by immunofluores-
cence double staining. The results showed that the ex-
pression of HVEM was found on CK-18+ epithelial cells
and CD68+ macrophages, but this expression was absent
on CD31+ endothelial cells, CD16+ monocytes, and CD3+
CD8+ T cells (Figure 4E).
Our previous work demonstrated that the expression
of several members of the B7 superfamily, including
PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H3 and B7-H4,
was also detected in liver biopsies from HBV-ACLF
patients [14,15]. In the current study, we examined
the relationships between HVEM and these members
of the B7 superfamily, and the results of this analysis
indicated that HVEM was co-expressed with all of
these molecules in liver sections from HBV-ACLF
patients (Figure 5).The relationships between BTLA-HVEM and FGL2 in
sections from HBV-ACLF
The hallmark of ACLF is the presence of sinusoidal
thrombosis and associated hepatocellular necrosis, these
phenomena are accompanied by the expression of virus-
induced FGL2 in the cells of the sinusoidal lining. The
FGL2 protein has the capacity to activate the coagulation
cascades directly, a function that has been described as
procoagulant activity (PCA) [4]. In this study, FGL2 ex-
pression was found in these HBV-ACLF samples, and
immunofluorescence double staining indicated that CK-18+
epithelial cells, CD68+ macrophages and CD31+ endothelial
cells are the major source of this protein. The expression of
BTLA/HVEM and FGL2 in HBV-ACLF sections was fur-
ther measured. The results demonstrated that both BTLA
and HVEM were co-expressed with FGL2 (Figure 6). Our
combined results revealed that both BTLA and HVEM
were enriched in HBV-ACLF patients, suggesting that
these molecules can be used as biomarkers for the
pathological diagnosis of HBV-ACLF.
Discussion
The BTLA/HVEM inhibitory pathway appears to be par-
ticularly important for balancing immune response and
Figure 5 The relationship between the expression of BTLA/HVEM and certain members of the B7 superfamily in liver tissue sections
from patients with HBV-related acute-on-chronic liver failure (HBV-ACLF). Immunofluorescence double staining indicated that several novel
members of the B7 superfamily, including PD-L1, PD-L2, B7-H3 and B7-H4, were co-expressed with HVEM. The arrows indicate positive cells. The
nuclei were stained with DAPI, and the scale bar indicates 20 μm.
Xu et al. Diagnostic Pathology 2012, 7:142 Page 6 of 9
http://www.diagnosticpathology.org/content/7/1/142tolerance in autoimmune diseases, tumor development,
transplantation, allergy and, in particular, the pathogen-
esis of viral infection [16-18]. Recent studies have sug-
gested that the BTLA/HVEM interaction functionally
regulates CMV-specific T cell functions [9]. Our previ-
ous work has also demonstrated that BTLA signaling
can maintain the survival of macrophages that are
infected with MHV-3, resulting in virus distribution and
tissue damage following MHV-3 infection [13]. ACLF is
a severe clinical syndrome characterized by coagulo-
pathy, jaundice and hepatic encephalopathy [19,20].
Most ACLF cases in China are associated with HBV
infection. In this study, we extended our research and
examined the expression of BTLA/HVEM in four cases
of HBV-ACLF patients. Immunohistochemical analysis
revealed that the expression of BTLA was dramatically
enhanced in liver samples from these HBV-ACLF
patients, and the positive cells were distributed through-
out the entire tissue. However, no positive cells wereobserved in the liver tissue of CHB patients or healthy
individuals. The phenotypes of BTLA+ cells were further
analyzed by immunofluorescence double staining, and
the results demonstrated that BTLA was expressed on
CK-18+ epithelial cells, CD31+ endothelial cells, CD68+
macrophages, CD56+ NK cells, CD16+ monocytes, CD3+
CD8+ T cells, and Foxp3+ regulatory T cells (Tregs).
Although the limitation of HBV-ACLF cases was
included here, the expression of BTLA was observed
on all of these four cases and these data strongly indi-
cates that BTLA may actively participate in regulating
the pathogenesis of this disease.
HVEM, the ligand of BTLA, is a novel member of the
TNF receptor superfamily, and its mRNA is broadly
expressed in both lymphoid and non-lymphoid tissues
[18]. The expression and distribution of HVEM in liver
biopsies from HBV and HBV-ACLF patients has not pre-
viously been reported. In this study, our data indicated
that HVEM was found in sections from HBV-ACLF and
Figure 6 The relationship between BTLA-HVEM and fibrinogen-like protein 2 (FGL2) expression in sections from patients with HBV-
related acute-on-chronic liver failure (HBV-ACLF). Immunofluorescence double staining demonstrated that FGL2 expression was observed in
CD31+ endothelial cells, CD68+ macrophages, and CK-18+ bile ducts of HBV-ACLF patients. Moreover, BTLA and HVEM were co-expressed with
FGL2. The arrows indicate positive cells. The nuclei were stained with DAPI, and the scale bar indicates 20 μm.
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filtrating cells, whereas HVEM was absent in sections
from normal individuals. Assessments using immuno-
fluorescence double staining further determined that
HVEM was expressed on CK-18+ epithelial cells and
CD68+ macrophages but completely absent on CD31+
endothelial cells, CD16+ monocytes, and CD3+ CD8+ T
cells. These results demonstrated that HVEM was
induced in certain antigen-presenting cells (APCs) in
these patients.
Our previous work has revealed that the expression of
several members of the B7 superfamily, including PD-L1
(B7-H1), PD-L2 (B7-DC), B7-H3 and B7-H4, wasfound in liver sections from HBV-ACLF [14,15]. PD-L1
and PD-L2 are two immunoregulatory molecules
belonging to the B7 superfamily that were identified as
ligands for PD-1. The binding of PD-L1 or PD-L2 with
PD-1 activates a signaling pathway that inhibits T cell
responses [21,22]. B7-H3 is a type I transmembrane pro-
tein that is expressed on activated macrophages, den-
dritic cells, monocytes and several types of cells in non-
lymphoid tissues [23]. B7-H3 promotes the proliferation,
cytotoxicity and IFN-γ production of T cells by cross-
linking with its hypothetical receptor and triggering the
receptor-mediated expression of myeloid cell-like tran-
script 2 (TLT-2) on activated T cells [23,24]. B7-H4 is a
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widely distributed in murine and human peripheral tis-
sues [25,26]. B7-H4−/− mice exhibited augmented Th1
responses and displayed lowered parasite burdens upon
Leishmania major and Listeria monocytogenes infection
compared with wild type mice, suggesting an inhibitory
role for B7-H4 in T cell responses [27,28]. In this study,
we also detected the relationships between HVEM and
these members of the B7 superfamily in sections from
HBV-ACLF, and the study results demonstrated that
HVEM was co-expressed with all of these molecules.
FGL2 is a critical molecule that promotes fibrinogen
deposition, which, in turn, activates the coagulation cas-
cades and thereby induces PCA, causing hepatocellular
necrosis during the development of fulminant virus
hepatitis [2]. High levels of FGL2+ cells that are distribu-
ted throughout the liver have also been observed in
HBV-ALCF patients. Phenotypic analyses indicated that
the expression of FGL2 was mainly localized to infiltrat-
ing CD68+ macrophages, CK-18+ bile ducts, and CD31+
capillaries. Moreover, both BTLA and HVEM were co-
expressed with FGL2, as assessed by immunofluores-
cence double staining.
To the best of our knowledge, this report is the first to
investigate the expression of BTLA and its ligand,
HVEM, in liver sections from HBV-ACLF patients. Our
results indicate that these molecules might be useful
diagnostic biomarkers for HBV-ACLF, and an under-
standing of the functional roles of these molecules could
aid in the development of novel strategies for disease
diagnosis or immunotherapy.Competing interests
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